Gene: MET

Alternate names for this Gene: AUTS9|DFNB97|HGFR|RCCP2|c-Met

Gene Summary: This gene encodes a member of the receptor tyrosine kinase family of proteins and the product of the proto-oncogene MET. The encoded preproprotein is proteolytically processed to generate alpha and beta subunits that are linked via disulfide bonds to form the mature receptor. Further processing of the beta subunit results in the formation of the M10 peptide, which has been shown to reduce lung fibrosis. Binding of its ligand, hepatocyte growth factor, induces dimerization and activation of the receptor, which plays a role in cellular survival, embryogenesis, and cellular migration and invasion. Mutations in this gene are associated with papillary renal cell carcinoma, hepatocellular carcinoma, and various head and neck cancers. Amplification and overexpression of this gene are also associated with multiple human cancers.

Gene is located in Chromosome: 7

Location in Chromosome : 7q31.2

Description of this Gene: MET proto-oncogene, receptor tyrosine kinase

Type of Gene: protein-coding

rs1858830 in MET gene and Blood Protein Measurement PMID 30072576 2018 Co-regulatory networks of human serum proteins link genetics to disease.

rs1057519824 in MET gene and Carcinoma PMID 12460923 2002 Novel somatic mutations of the MET oncogene in human carcinoma metastases activating cell motility and invasion.

PMID 9826708 1998 Uncoupling signal transducers from oncogenic MET mutants abrogates cell transformation and inhibits invasive growth.

PMID 1104268 1975 The radiology of osseous and articular infection.

PMID 10417759 1999 Novel mutation in the ATP-binding site of the MET oncogene tyrosine kinase in a HPRCC family.

rs121913675 in MET gene and Liver carcinoma PMID 9927037 1999 Somatic mutations in the kinase domain of the Met/hepatocyte growth factor receptor gene in childhood hepatocellular carcinomas.

rs1057519824 in MET gene and Neoplasms PMID 17483355 2007 An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms.

rs121913668 in MET gene and Neoplastic Syndromes, Hereditary PMID 10327054 1999 Novel mutations of the MET proto-oncogene in papillary renal carcinomas.

PMID 9326629 1997 Activating mutations for the met tyrosine kinase receptor in human cancer.

PMID 11354004 2001 Structural basis of oncogenic activation caused by point mutations in the kinase domain of the MET proto-oncogene: modeling studies.

PMID 9140397 1997 Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas.

PMID 24061647 2013 The novel ATP-competitive inhibitor of the MET hepatocyte growth factor receptor EMD1214063 displays inhibitory activity against selected MET-mutated variants.

PMID 24121490 2013 The HSP90 inhibitor ganetespib synergizes with the MET kinase inhibitor crizotinib in both crizotinib-sensitive and -resistant MET-driven tumor models.

PMID 15371818 2004 Early onset hereditary papillary renal carcinoma: germline missense mutations in the tyrosine kinase domain of the met proto-oncogene.

PMID 10433944 1999 Hereditary and sporadic papillary renal carcinomas with c-met mutations share a distinct morphological phenotype.

PMID 10417759 1999 Novel mutation in the ATP-binding site of the MET oncogene tyrosine kinase in a HPRCC family.

PMID 11927612 2002 Dysregulation of Met receptor tyrosine kinase activity in invasive tumors.

rs121913668 in MET gene and Renal Cell Carcinoma PMID 9140397 1997 Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas.

rs121913243 in MET gene and Renal carcinoma PMID 25157968 2014 Prospective enterprise-level molecular genotyping of a cohort of cancer patients.

PMID 23213094 2013 Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma.

PMID 18829470 2008 Single-agent and combination therapeutic strategies to inhibit hepatocyte growth factorMET signaling in cancer.

PMID 23610116 2013 Initial clinical sensitivity and acquired resistance to MET inhibition in MET-mutated papillary renal cell carcinoma.

PMID 11750879 2002 Role of the hepatocyte growth factor receptor, c-Met, in oncogenesis and potential for therapeutic inhibition.

rs41741 in MET gene and Serum gamma-glutamyl transferase measurement PMID 29403010 2018 Genetic analysis of quantitative traits in the Japanese population links cell types to complex human diseases.

rs794728016 in MET gene and Severe hearing loss PMID 25941349 2015 A mutation of MET, encoding hepatocyte growth factor receptor, is associated with human DFNB97 hearing loss.

rs38855 in MET gene and Triglycerides measurement PMID 28334899 2017 Association analyses of East Asian individuals and trans-ancestry analyses with European individuals reveal new loci associated with cholesterol and triglyceride levels.

PMID 24097068 2013 Discovery and refinement of loci associated with lipid levels.

rs121913243 in MET gene and Type 1 Papillary Renal Cell Carcinoma PMID 24319509 2013 Canadian guideline on genetic screening for hereditary renal cell cancers.

PMID 10433944 1999 Hereditary and sporadic papillary renal carcinomas with c-met mutations share a distinct morphological phenotype.

PMID 10327054 1999 Novel mutations of the MET proto-oncogene in papillary renal carcinomas.

PMID 25394175 2015 A practice guideline from the American College of Medical Genetics and Genomics and the National Society of Genetic Counselors: referral indications for cancer predisposition assessment.

PMID 9140397 1997 Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas.

PMID 10417759 1999 Novel mutation in the ATP-binding site of the MET oncogene tyrosine kinase in a HPRCC family.

PMID 9563489 1998 Two North American families with hereditary papillary renal carcinoma and identical novel mutations in the MET proto-oncogene.

rs1476454 in MET gene and White Blood Cell Count procedure PMID 30595370 2019 Leveraging Polygenic Functional Enrichment to Improve GWAS Power.